Nachang Third Hospital
Welcome,         Profile    Billing    Logout  
 18 Trials 
14 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Hong
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Recruiting
3
350
RoW
601 1.25mg, 601, ranibizumab 0.5mg, Lucentis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT06196840: Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Active, not recruiting
2
50
RoW
LX102 subretinal injection, Aflibercept intravitreal injection
Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration
07/25
10/29
NCT06212297: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Active, not recruiting
1/2
9
RoW
LX101
Innostellar Biotherapeutics Co.,Ltd
Inherited Retinal Dystrophy
02/25
03/29
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Recruiting
1/2
268
RoW
TY101
Tayu Huaxia Biotech Medical Group Co., Ltd.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
06/24
07/25
NCT06198413: LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Active, not recruiting
1
12
RoW
LX102 subretinal injection
Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration
12/24
01/29
NCT05715333: Study of CM326 Injection in Healthy Subjects

Completed
1
46
RoW
CM326, Placebo
Keymed Biosciences Co.Ltd
Healthy
10/23
10/23
NCT06432738: ZL-82 Double-blind Clinical Trial

Recruiting
1
40
RoW
ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo
Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Person
08/24
12/24
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Completed
1
240
RoW
CM310
Keymed Biosciences Co.Ltd
Healthy
07/23
07/23
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Hong
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Recruiting
3
350
RoW
601 1.25mg, 601, ranibizumab 0.5mg, Lucentis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT06196840: Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Active, not recruiting
2
50
RoW
LX102 subretinal injection, Aflibercept intravitreal injection
Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration
07/25
10/29
NCT06212297: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Active, not recruiting
1/2
9
RoW
LX101
Innostellar Biotherapeutics Co.,Ltd
Inherited Retinal Dystrophy
02/25
03/29
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Recruiting
1/2
268
RoW
TY101
Tayu Huaxia Biotech Medical Group Co., Ltd.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
06/24
07/25
NCT06198413: LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Active, not recruiting
1
12
RoW
LX102 subretinal injection
Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration
12/24
01/29
NCT05715333: Study of CM326 Injection in Healthy Subjects

Completed
1
46
RoW
CM326, Placebo
Keymed Biosciences Co.Ltd
Healthy
10/23
10/23
NCT06432738: ZL-82 Double-blind Clinical Trial

Recruiting
1
40
RoW
ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo
Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Person
08/24
12/24
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Completed
1
240
RoW
CM310
Keymed Biosciences Co.Ltd
Healthy
07/23
07/23
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28

Download Options